Phase 2Enrolling by invitation
Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women (AFFIRM)
AFFIRM: A Phase 2 Randomized, Placebo-Controlled Study of Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women
- Sponsor
- Mayo Clinic (Academic or other)
- Enrolment
- 40 planned
- Conditions
- Frail Elderly Syndrome
- Interventions
- Fisetin; Placebo oral capsule
- Ages
- older adults
- Registry
- NCT03430037
From the registry
This is a pilot study to evaluate whether targeting inflammation will help reduce markers of insulin resistance inflammation, bone resorption and physical dysfunction in elderly women with gait disturbance. Positive results of this study would lead to the development of a larger clinical trial examining the effects of this intervention on age-related dysfunction.
Primary outcomes
- Improved 6 minute walk